Novel Pharmacological Targets of Post-Traumatic Stress Disorders
Authors:
- Donatella MarazzitiDonatella Marazziti
- Claudia CarmassiClaudia Carmassi
- Gabriele CappellatoGCGabriele Cappellato
- Ilaria ChiarantiniICIlaria Chiarantini
- Leonardo MassoniLeonardo Massoni
- Federico MucciFMFederico Mucci
- Alessandro AroneAlessandro Arone
- Miriam VioliMVMiriam Violi
- Stefania PalermoSPStefania Palermo
- Giovanni De IorioGIGiovanni De Iorio
- Liliana Dell’ossoLiliana Dell’osso
Open Access
Abstract
Post-traumatic stress disorder (PTSD) is a psychopathological condition with a heterogeneous clinical picture that is complex and challenging to treat. Its multifaceted pathophysiology still remains an unresolved question and certainly contributes to this issue. The pharmacological treatment of PTSD is mainly empirical and centered on the serotonergic system. Since the therapeutic response to prescribed drugs targeting single symptoms is generally inconsistent, there is an urgent need for novel pathogenetic hypotheses, including different mediators and pathways. This paper was conceived as a narrative review with the aim of debating the current pharmacological treatment of PTSD and further highlighting prospective targets for future drugs. The authors accessed some of the main databases of scientific literature available and selected all the papers that fulfilled the purpose of the present work. The results showed that most of the current pharmacological treatments for PTSD are symptom-based and show only partial benefits; this largely reflects the limited knowledge of its neurobiology. Growing, albeit limited, data suggests that the hypothalamic-pituitary-adrenal axis, opioids, glutamate, cannabinoids, oxytocin, neuropeptide Y, and microRNA may play a role in the development of PTSD and could be targeted for novel treatments. Indeed, recent research indicates that examining different pathways might result in the development of novel and more efficient drugs.Keywords
This publication has 136 references indexed in Scilit:
- Plasma Concentrations of Endocannabinoids and Related Primary Fatty Acid Amides in Patients with Post-Traumatic Stress DisorderPLOS ONE, 2013
- MicroRNA-182 Regulates Amygdala-Dependent Memory FormationJournal of Neuroscience, 2013
- Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapyNeuropharmacology, 2012
- Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorderTrends in Neurosciences, 2012
- Epigenetic modification of hippocampal Bdnf DNA in adult rats in an animal model of post-traumatic stress disorderJournal of Psychiatric Research, 2011
- Persistent anxiolytic affects after chronic administration of the CRF1 receptor antagonist R121919 in ratsNeuropharmacology, 2011
- Amygdala intercalated neurons are required for expression of fear extinctionNature, 2008
- Historical approaches to post-combat disordersPhilosophical Transactions of the Royal Society B: Biological Sciences, 2006
- SSRIs versus Non-SSRIs in Post-traumatic Stress DisorderDrugs, 2004
- Glutamate receptor function in learning and memoryBehavioural Brain Research, 2003